Project CBD

AUGUST 4, 2021

Scientists are studying psilocybin and LSD to treat migraines and cluster headaches.

298

298

Veriheal

JUNE 19, 2023

A recent study on the global psychedelics market conducted by Brandessence Market Research has revealed that earnings are anticipated to hit $12 billion by 2029. The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons.

Therapy 105

Therapy Treatment Patients Policy 105

Veriheal

SEPTEMBER 2, 2021

Those of you who have had a migraine before will know that it is much more than pain. Migraine treatments are significantly unsuccessful so the fact that cannabis and psilocybin present as potentially effective treatments is quite important for those in need of relief. Researching Psilocybin for Migraines.

Treatment 95

Treatment Microdosing Therapy Patients 95

The Cannigma

DECEMBER 12, 2022

Psychedelics were first discovered by indigenous cultures surveying the land for resources. Now, psychedelic research is booming. How do psychedelics work? How do psychedelics work? Psychedelics that work this way are often called “classical” psychedelics, and are known to produce a “trip.”.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JANUARY 6, 2022

CNSX : FTRP; OTCMKTS : FTRPF), a global leader in the development and delivery of psychedelic therapies, today announced that it will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada’s Special Access Program (SAP). Field Trip Health Ltd.

Access 52

Access Patients Therapy Conditions 52

Cannabis Law Report

JULY 6, 2021

Evan Lewis said they plan to expand NCT into a comprehensive clinical neurology treatment center with a unique specialization in the application of psychedelics in the field of neurology. “In doing so, this collaborative discipline could potentially make a transformative difference for many patients.”

Therapy 66

Therapy Research and Development Treatment Patients 66

Cannabis Law Report

OCTOBER 1, 2021

Ahmad Doroudian, CEO of BetterLife, commented, “The inventions covered by this provisional patent filing hold great promise, and helps us advance on our path to becoming a leader in the psychedelic drug space which is estimated to become a US$6.85-billion billion industry by 2027. The global depression drugs market reached US$12.41

Treatment 52

Treatment Conditions Media 52